Half-Year 2022 Financial and Clinical Trials Update

Roche Group development pipeline Phase I (49 NMES + 11 Als) RG6007 RG6026 RG6058 HLA-A2-WT1 x CD3 glofitamab monotherapy + combos tiragolumab combos AML RG7828 heme tumors heme & solid tumors RG6129 RG6160 RG6171 RG6076 CD19-4-1BBL combos HLA-A2-MAGE-A4 x CD3 cevostamab (FcRH5 x CD3) giredestrant (SERD) heme tumors CHU CHU Lunsumio (mosunetuzumab) monotheraphy + combos FIXa x FX RG6026 glofitamab +chemo heme tumors glypican-3 x CD3 solid tumors CHU codrituzumab hemophilia solid tumors HCC RG6058 tiragolumab + T tiragolumab +T+chemo tiragolumab +T+chemo tiragolumab +T r/r multiple myeloma CHU CD137 switch antibody solid tumors tiragolumab + T solid tumors CHU LUNA18 solid tumors RG6114 RG6156 inavolisib (mPI3K alpha inh) EGFRvIII x CD3 CHU SPYK04 solid tumors solid tumors SQZ PBMC vaccine glioblastoma solid tumors RG6287 IBD RG6180 autogene cevumeran + T solid tumors RG6341 asthma RG6185 belvarafenib (pan-RAF inh) + Cotellic + T solid tumors RG6107 RG6139 RG6180 RG6354 RG6357 crovalimab PD1 x LAG3 SPK-8011 RG6418 RG6189 FAP-CD40 ±T solid tumors selnoflast (NLRP3 inh) inflammation RG6194 runimotamab (HER2 x CD3) BC RG6315 RG7828 immunologic disorders Lunsumio (mosunetuzumab) RG6234 GPRC5D x CD3 multiple myeloma RG7880 efmarodocokin alfa SLE aGVHD RG6264 Phesgo OBI HER2+ BC RG6358 RG7601 CHU RG6149 SPK-8016 Venclexta + carfilzomib Oncolytic Type 5 adenovirus RG6006 Abx MCP astegolimab (Anti-ST2) bacterial infections RG6279 PD1-IL2v + T solid tumors RG6319 LepB inhibitor RG6299+ ASO factor B complicated urinary tract infection autogene cevumeran + pembrolizumab zinpentraxin alfa (PRM-151) hemophilia A with inhibitors to factor VIII r/r MM t(11;14) esophageal cancer COPD IgA nephropathy Phase II (22 NMES + 11 Als) Roche 1L ctDNA high risk DLBCL NSCLC 1L non-squamous NSCLC NSCLC neoadj-adj cervical cancer 1L PD-L1+mSCCHN sickle cell disease solid tumors 1L melanoma myelofibrosis hemophilia A RG6286 colorectal cancer RG7854/RG79 RG6035 BS-CD20 MAb RG6290 MAGE-A4 ImmTAC + T solid tumors RG6091 RG6292 CD25 MAb ±T solid tumors rugonersen (UBE3A LNA) multiple sclerosis Angelman syndrome TLR7 ago(3)/CPAM (2)/ 07/RG6346/ HBV RG60841 siRNA/PDL1 LNA RG6163 psychiatric disorders RG6359 SPK-3006 Pompe disease RG6323 IL15/IL15Ra-Fc + T solid tumors RG6182 RG6330 KRAS G12C solid tumors RG6237 latent myostatin RG6333 CD19 x CD28+ glofitamab r/r NHL RG6289 RG6344 BRAF inhibitor (3) solid tumors RG7637 RG6392 RG6433 SHP2i RG6440 TGFB (SOF 10) RG6526** camonsertib RG7446 Morpheus platform oncology solid tumors solid tumors solid tumors solid tumors RG6120 VEGF-Ang2 DutaFab RG7601 Venclexta + azacitidine r/r MDS RG6312 RG6351 RG6501* RG7921 CHU NME OpRegen neurodegenerative diseases neuromuscular disorders Alzheimer's neurodevelopmental disorders nAMD geographic atrophy retinal disease geographic atrophy nAMD RG6100 semorinemab Alzheimer's RG6102 BS-gantenerumab Alzheimer's RG6237 latent myostatin + Evrysdi SMA RG6416 bepranemab Alzheimer's RG7412 crenezumab familial Alzheimer's healthy pts RG7816 alogabat (GABA Aa5 PAM) ASD RG7906 ralmitaront RG7935 prasinezumab AMY109 endometriosis RG7802 cibisatamab + T solid tumors RG6147 RG6179 RG7774 galegenimab (HtrA1) RG7827 FAP-4-1BBL monotherapy + combos solid tumors RG6299+ ASO factor B schizophrenia Parkinson's geographic atrophy DME retinal disease geographic atrophy 1combination platform Status as of July 21, 2022 New Molecular Entity (NME) Additional Indication (Al) Oncology/Hematology Immunology Infectious Diseases Metabolism Neuroscience Ophthalmology Other CHU Chugai managed +IONIS managed SQZ-SQZ Biotechnology managed *Lineage Cell Therapeutics managed **Repare Therapeutics managed RG-No-Roche/Genentech T=Tecentriq BS Brain Shuttle OBI-On-Body Delivery System 74

View entire presentation